Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia

Clinical Infectious Diseases

Volumn 46, Issue 8, 2008, Pages 1157-1164

  Giamarellos Bourboulis, Evangelos J ^a,c   Pechère, Jean Claude ^b   Routsi, Christina ^a   Plachouras, Diamantis ^a   Kollias, Spyridon ^a   Raftogiannis, Maria ^a   Zervakis, Dimitrios ^a   Baziaka, Fotini ^a   Koronaios, Apostolos ^a   Antonopoulou, Anastasia ^a   Markaki, Vassiliki ^a   Koutoukas, Pantelis ^a   Papadomichelakis, Evangelos ^a   Tsaganos, Thomas ^a   Armaganidis, Apostolos ^a   Koussoulas, Vassilios ^a   Kotanidou, Anastasia ^a   Roussos, Charis ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSPASM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; SEPSIS; TREATMENT OUTCOME;

EID: 42549119145     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/529439     Document Type: Article

References (31)

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-73.
2. Vincent J-L, Sun Q, Dubois M-J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-93.
3. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54:21-8.
4. Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 2002; 49:745-55.
5. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48:93-9.
6. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 2005; 25:168-72.
7. Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 2005; 37:48-54.
8. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistantPseudomonas aeruginosa. BMC Infect Dis 2006; 6:31.
9. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2006; 57:937-44.
10. Woske HJ, Röding T, Schulz I, Lode H. Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. Crit Care 2001; 5:167-73.
11. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005; 127:589-97.
12. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
13. Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001; 120:955-70.
14. Baughman RP. Diagnosis of ventilator-associated pneumonia. Curr Opin Crit Care 2003; 9:397-402.
15. Vincent JL. Ventilator-associated pneumonia. J Hosp Infect 2004; 57:272-80.
16. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-9.
17. Levy M, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6.
18. Clarithromycin for intravenous injection: clinical expert report [data on file]. Abbott Park, IL: Abbott Laboratories, 1998.
19. Camargo LFA, De Marco FV, Barbas CSV, et al. Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates. Crit Care 2004; 8:R422-30.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 15th international supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2005; 25:34-65.
21. Madars-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the role of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006; 27:155-69.
22. Kollef MH, Shorr A, Tabak YP, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results froma large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
23. WHONET Greece. The Greek system for surveillance of antimicrobial resistance. Available at: http://www.mednet.gr/whonet/. Accessed 22 May 2007.
24. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005; 31:1488-94.
25. Rello J, Lorente C, Diaz E, et al. Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest 2003; 124:2239-43.
26. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
27. Saiman L, Marshall BC, Mayer-Hamblett, et al. Azithromycin: in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749-56.
28. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002; 360:978-84.
29. Asgrimsson V, Gudjonsson T, Gudmundsson GH, Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother 2006; 50:1805-12.
30. Takeda K, Standiford TJ, Pechère JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum sensing inhibitors. Curr Pharm Des 2004; 10:3055-65.
31. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29:91-7.